Clinical Trial Update: A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults [Phase 1]

View source ↗

Summary

Pfizer completed a Phase 1 study evaluating the safety and potential efficacy of 20vPnC and 13vPnC pneumococcal vaccines in Chinese adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• 13vPnC
• 20vPnC (20-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 1 | Status: COMPLETED